Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
47
IRD Quote, Financials, Valuation and Earnings
Last price:
$2.24
Seasonality move
:
-17.2%
Day range:
$2.06 - $2.29
52-week range:
$0.65 - $2.37
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
7.60x
P/B ratio:
25.77x
Volume:
382.9K
Avg. volume:
483.1K
1-year change:
85.83%
Market cap:
$153.8M
Revenue:
$11M
EPS (TTM):
-$1.72
Analysts' Opinion
-
Consensus RatingOpus Genetics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $7.67, Opus Genetics, Inc. has an estimated upside of 243.8% from its current price of $2.23.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $6.00 representing 100% downside risk from its current price of $2.23.
Fair Value
-
According to the consensus of 8 analysts, Opus Genetics, Inc. has 243.8% upside to fair value with a price target of $7.67 per share.
IRD vs. S&P 500
-
Over the past 5 trading days, Opus Genetics, Inc. has overperformed the S&P 500 by 10.27% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Opus Genetics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Opus Genetics, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Opus Genetics, Inc. reported revenues of $3.1M.
Earnings Growth
-
Opus Genetics, Inc. has grown year-over-year earnings for 3 quarters straight. In the most recent quarter Opus Genetics, Inc. reported earnings per share of -$0.25.
Enterprise value:
124M
EV / Invested capital:
17.63x
Price / LTM sales:
7.60x
EV / EBIT:
--
EV / Revenue:
8.48x
PEG ratio (5yr expected):
-0.02x
EV / Free cash flow:
-3.78x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$14.6M
Return On Assets:
-170.31%
Net Income Margin (TTM):
-466.09%
Return On Equity:
-490.41%
Return On Invested Capital:
-312.03%
Operating Margin:
-269.93%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $57.2M | $8.4M | $14.6M | $3.9M | $3.1M | |
| Gross Profit | $57.2M | $1.7M | $14.6M | -- | $3.1M | |
| Operating Income | $29.1M | -$29.5M | -$37.2M | -$8M | -$8.3M | |
| EBITDA | $29.1M | -$29.5M | -$37.1M | -$8M | -$8.3M | |
| Diluted EPS | $1.32 | -$1.09 | -$1.72 | -$0.29 | -$0.25 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $23.2M | $14.6M | $54.2M | $40.4M | $35.9M | |
| Total Assets | $23.2M | $14.6M | $54.2M | $40.4M | $36.1M | |
| Current Liabilities | $2.6M | $2.7M | $3.9M | $6.1M | $29.1M | |
| Total Liabilities | $2.6M | $2.7M | $3.9M | $6.1M | $30.2M | |
| Total Equity | $20.6M | $11.9M | $50.3M | $34.3M | $6M | |
| Total Debt | -- | -- | -- | -- | $1.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $23.1M | -$13.6M | -$32.9M | -$5.1M | -$6.2M | |
| Cash From Investing | -- | -- | $1.2M | -- | -- | |
| Cash From Financing | $5.4M | $7.9M | $25.8M | $353K | $4.5M | |
| Free Cash Flow | $23.1M | -$13.6M | -$32.9M | -$5.1M | -$6.2M | |
IRD
Sector
Market Cap
$153.8M
$28.4M
Price % of 52-Week High
94.09%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
-23.52%
-1.32%
1-Year Price Total Return
85.83%
-22.19%
Beta (5-Year)
0.418
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$2.06
200-day SMA
Buy
Level
$1.29
Bollinger Bands (100)
Buy
Level
1.21 - 1.99
Chaikin Money Flow
Buy
Level
3.6M
20-day SMA
Buy
Level
$1.97
Relative Strength Index (RSI14)
Buy
Level
63.05
ADX Line
Buy
Level
17.45
Williams %R
Sell
Level
-10.1695
50-day SMA
Buy
Level
$1.97
MACD (12, 26)
Buy
Level
0.09
25-day Aroon Oscillator
Sell
Level
-44
On Balance Volume
Neutral
Level
1.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-6.4545)
Sell
CA Score
(Annual)
Level (-3.186)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (9.0247)
Sell
Piotroski F Score
(Annual)
Level (2)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Opus Genetics, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Durham, NC.
Stock Forecast FAQ
In the current month, IRD has received 8 Buy ratings 0 Hold ratings, and 0 Sell ratings. The IRD average analyst price target in the past 3 months is $7.67.
-
Where Will Opus Genetics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Opus Genetics, Inc. share price will rise to $7.67 per share over the next 12 months.
-
What Do Analysts Say About Opus Genetics, Inc.?
Analysts are divided on their view about Opus Genetics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Opus Genetics, Inc. is a Sell and believe this share price will drop from its current level to $6.00.
-
What Is Opus Genetics, Inc.'s Price Target?
The price target for Opus Genetics, Inc. over the next 1-year time period is forecast to be $7.67 according to 8 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is IRD A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Opus Genetics, Inc. is a Buy. 8 of 8 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of IRD?
You can purchase shares of Opus Genetics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Opus Genetics, Inc. shares.
-
What Is The Opus Genetics, Inc. Share Price Today?
Opus Genetics, Inc. was last trading at $2.24 per share. This represents the most recent stock quote for Opus Genetics, Inc.. Yesterday, Opus Genetics, Inc. closed at $2.23 per share.
-
How To Buy Opus Genetics, Inc. Stock Online?
In order to purchase Opus Genetics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get IRD Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
IRD
Sector
P/E ratio
--
23.66x
PEG ratio
-0.02x
-0.01x
P/B ratio
25.77x
1.84x
Price / LTM sales
7.60x
1.60x
Growth Metrics
IRD
Sector
Revenue growth
-20.38%
4.85%
Earnings growth
14.17%
11.15%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.13
-$0.20
Profitability
IRD
Sector
Profitability FY 2024
$11M
$3.6M
Return on invested capital
-312.03%
-30.98%
Return on assets
-170.31%
-27.62%
Return on equity
-490.41%
-36.69%
Earnings Date
Last Earnings Date
May
8
Next Earnings Date
Dec
5
Estimated Next Earnings Date
Mar
6
Balance Sheet
IRD
Sector
Total cash
$30.8M
$27.2M
Short term investments
$2K
$25.7M
Total assets
$36.9M
$79.9M
Long term debt
$1.1M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 18.9% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
